Try our Advanced Search for more refined results
Life Sciences - July, 2018
320 articles
- Janssen Loses Remicade Patent Case To Pfizer, Celltrion
- Monsanto Expert Rips Studies Linking Herbicide To Cancer
- OvaScience Can't Escape Investor IVF Treatment Suit
- Insys Founder Tries To Exit Suit Over Drug-Related Death
- Allergan Says Imprimis' Bad Faith Discovery Merits Sanctions
- FDA Warning Wire: Um, Don't Make Medicines In Kitchen Pots
- PTAB Must Redo Suboxone Patent Reviews Post-SAS
- Merck Says Vaccine Bundles Caused Low Prices, Not Harm
- Trends And Predictions For Serial Biologic Drug IPR Petitions
- Pharma Co. Duped Investors In $61M Offering, Suit Says
- Lawyers Compete To Represent Zetia Buyers In Antitrust Case
- Ex-Biotech CEO A 'Total Moron' But No Crook, NY Jury Hears
- Jury Awards Hologic $5M For NovaSure Patent Infringement
- FDA Rejects Insys Painkiller Spray Over Safety Concerns
- PTAB Nixes CardioNet Unit's Heart Monitor Patent
- Israeli Pharma Co. To Pay $2M To End Stock-Drop Suit
- FDA Sounds Alarm Over 'Vaginal Rejuvenation' Treatments
- Morgan Lewis Nabs 7-Partner IP Team From McDermott
- For Self-Driving Car Makers, Industry Standards Matter
- Law360 Names Top Attorneys Under 40
- Pomerantz Named Lead Counsel In Antares Pharma Fraud Suit
- Individualized Claims Thwart Testosterone RICO MDL
- Monsanto Herbicide's Link To Cancer Sound, Jury Told
- Ex-Insys Execs Say Feds' Bid To Redo RICO Case Is Futile
- Tibet Pharma Investors Escape Dismissal For Now In IPO Row
- Anthem, Express Scripts Were Fiduciaries, 2nd Circ. Hears
- Sandoz Holds Back On Cataract Drug Generic, Ending IP Suit
- GOP Lawmakers Seek FTC Scrutiny Of Drug Benefit Managers
- Czechs Say Dutch Ruling Backs $374M Award's Dismissal
- J&J Unit Can't Skip To En Banc Hearing In Pa. Mesh Appeal
- FTC Says Drugmakers Must Face AndroGel Antitrust Suit
- Innovator Liability Flunks The Dormant Commerce Clause
- AbbVie Investors Sue Over 1-Day $100M Stock Drop
- Fed. Circ. Nixes USPTO Bid For Win-Or-Lose Attys' Fees
- Monsanto's Toxicology Figures Don't Hold Up, Jury Hears
- Drugmaker Put 'Misbranded' Medicines On Market, Feds Say
- AstraZeneca Sues Over Generic Breast Cancer Drug
- J&J Can't Get New Judge For Philly Pelvic Mesh Trial
- E-Commerce Co. Pinduoduo Leads 7 IPOs Totaling $2.7B
- Warning Claims Axed In Bard Blood Vessel Filter Bellwether
- Judge Slams 'Stupid Argument' In Bid To DQ Shkreli Attys
- UK Tribunal Won't Pause Epilepsy Drug Case For Appeals
- Media Can't Access Drug Co. Data In Opioid MDL
- What You Need To Know About Trump's EU Trade Epiphany
- King & Spalding Nabs IP Partner From Paul Hastings
- Shkreli Atty Deserves At Least 5 Years In Prison, Feds Say
- Bristol-Myers Unlikely To Shake Up Class Action Landscape
- The Future Of Authenticating Audio And Video Evidence
- Pharma Statisticians Say Insider Trading Trial Was Tainted
- House Votes To Extend Exemption From ACA Insurer Fee
- Clint Eastwood Sues Medical Co. For Patent Investments
- Gene Editing Co. Bluebird Bio Offers 3.4M Shares At $162
- Discovery War Breaks Out In Opioid MDL Bellwethers
- Novo Nordisk Says Execs Didn't Hide Insulin Sales Woes
- EU, US Making A Bid To Cool Rising Trade Tensions
- USCIS Policy Changes Put STEM Students On Shaky Footing
- Fenwick-Led Bloom Energy Leads 2 IPOs Raising $337.5M
- Boston Scientific Chips Away At Nevro Patents, Beats IP Suit
- Wis. Tribe Reaches Deal With State Over Hemp Program
- From Billable Hours To Bedtime Stories: Lawyering With Children
- Calif. Rules For Advising Cannabis Clients Need Clarity: Part 2
- Must Whole Patent Be Nixed To Forfeit 180-Day Exclusivity?
- Minn. Tribe Sues Drugmakers, Distributors Over Opioid Crisis
- Feds Try To Clear Up Ex-Insys Execs' RICO Charge For Judge
- 2nd Circ. Nixes Class Cert. In J&J 'Natural' Baby Wash Suit
- Bitter Dissent Shreds Rehearing Denial In Md. Drug Price Row
- How Mammoth Student Loans Are Dogging Today's Lawyers
- FDA To Mull New Ideas On Biosimilar Competition, Approvals
- New Risks For US Cos. Inadvertently Supporting North Korea
- Calif. Rules For Advising Cannabis Clients Need Clarity: Part 1
- Reed Smith Adds Norton Rose Health Care Privacy Pro
- A Clever Scheme To Protect Invalid Patents Has Failed
- Law360's Global 20 Doesn't Acknowledge Global Networks
- Grant & Eisenhofer Not Entitled To $31M Fee, Ex-Client Says
- Monsanto's Herbicide Caused Open Lesions, Jury Hears
- Bayer Can't Keep 16 Suits Over Essure Injuries In Fed. Court
- I-MAK Strikes Out In Final Gilead Hep C Patent Challenge
- Perkins Coie Nabs Dorsey & Whitney VC Pro In Silicon Valley
- Fed. Circ. Tribal Ruling Puts State PTAB Immunity In Doubt
- FTC To Seek Revival Of Parts Of AbbVie Suit After $448M Win
- Fed. Circ. Prior Art Ruling Illegal, Ariosa Tells Justices
- Time For Sunshine On 3rd-Party Litigation Funding
- BioChemics Wants More Time To Come Up With SEC's $17M
- Theranos Settles Indirect Investors' Fraud Suit
- Is The Grass Greener On The Solo Side?
- 1st Circ. Wonders Why FDA Should Not Decide Eyedrop Suit
- Real Estate Brokerage Leads 4 IPO Launches Exceeding $1.2B
- NJ Justices Won't Review Toss Of $25M Accutane Verdict
- China's New Medical Device Regulations Bring Big Changes
- Law360's Satisfaction Survey: By The Numbers
- The Least-Stressed Attorneys In A Stressed-Out Profession
- Acadia Hit With Securities Suit Over Drug Linked To Deaths
- Oncologist Says Roundup Caused Groundskeeper's Cancer
- Pharma Co. Can Peek At Just 1 Email In Cancer Research Suit
- Greenberg Traurig Adds Former Teva Atty To Philly Office
- 11 Firms To Steer IPOs Topping $3B In Busy Summer Stretch
- J&J Faces Bid To Revive Cancer Victim's $417M Talc Win
- Endo, Mallinckrodt Target Drug Dealers With Opioid Suit
- Keryx Trims, But Can't Scrap Shareholder Stock-Drop Suit
- Ariosa Can't Shake $27M Verdict In Illumina Prenatal IP Row
- Faulty Expert Opinion Tanks Auxilium Testosterone Suit
- Morgan Lewis-Guided Biotech Firm Scores $101.5M From IPO
- Full Fed. Circ. Should Nix UCB's Vimpat Patent, Accord Says
- United, Next Health Denied Dismissals In $100M Fraud Suit
- GlaxoSmithKline Says FDA Rejected Zofran Birth Defects
- Health Hires: Wilson Sonsini, Ropes & Gray, Kirkland & Ellis
- PE-Backed UPL To Acquire Crop Solutions Biz For $4.2B
- What Directors Need To Include In Appraisal Notices
- Judge OKs $54M Aggrenox Settlement In Pay-For-Delay Suit
- The Opioid Epidemic: Who Will Jurors Hold Accountable?
- Fed. Circ. Says Tribal Immunity Doesn't Apply In IPR
- Suddenly, ALJs Become Political Appointees
- Hernia Mesh Maker Takes IP Suit Coverage Row To 3rd Circ.
- Genomic Cancer Testing Cos. Settle IPRs, Infringement Suit
- Cooley-Led Cannabis Co. Leads 5 IPOs Raising $446M
- Asbestos Link In $4.7B J&J Verdict Adds Twist To Talc Suits
- Medtronic Strikes $43M Deal To End Stock-Drop Suit
- Class Attorneys Secure $40M From Solodyn Pay-For-Delay
- Pharma Charity Likely Waived Free Speech Right, OIG Says
- Tendyne Investors Sue Abbott Over $50M Merger Bonus Miss
- Deals Rumor Mill: Fosun, UnitedHealth, Niu
- AngioDynamics Will Pay $12.5M To End DOJ's FCA Probe
- Genentech Drops Bid For White & Case Samsung Docs
- HHS Looks To Imports As Remedy For Drug Price Increases
- AbbVie Judge Rejects Interest Hike On AndroGel Penalty
- A Lawyer's Guide To Genomics In Toxic Tort Cases: Part 3
- PTAB Urged To Review CRISPR Gene-Editing Patent
- Cancer Pro To Monsanto Jury: Pesticide Study Critique 'Idiotic'
- Top Gov't Contracts Policy Changes So Far In 2018
- Goodwin-Led Biotech Tops 3 IPOs Totaling $384M
- No New Trial For 2 Convicted In Valeant Fraud
- Discovery In Opioid MDL Bellwethers Gets Big Haircut
- Opioid Distributors Can't Escape Counties' Suit
- Addiction Doesn't Keep Embezzling Union Rep Out Of Prison
- Deals Rumor Mill: IHeartMedia, Astellas, Aramco
- FDA Chief Blames Big Pharma For 'Anemic' Biosimilars Sales
- Jury Convicts Accountant Of Aiding Biotech VC In $18M Fraud
- A Chat With Gibson Dunn Diversity Chief Salim-Williams
- Mallinckrodt Looks To Exit Investor Suit Over Antitrust Deal
- A Lawyer's Guide To Genomics In Toxic Tort Cases: Part 2
- Congressional Forecast: July
- What Kavanaugh's Writing Tells Us About His Personality
- SEC Says Bio-Security Firm Owes It $19.7M In Fraud Case
- Employee Performance Ratings: Tainted Or Sainted?
- Federal Claims Court Says Drugmaker Can Sell Meds To VA
- Top Gov't Contracts Cases Of 2018 So Far
- EPA Official Tried To 'Kill' Pesticide Study, Monsanto Jury Told
- Drug Wholesalers Denied Class Cert. In AndroGel Suit
- Ex-Katten Atty Says Prison Unnecessary For Shkreli Fraud
- Product Liability Cases To Watch: Midyear Report
- DC Circ. Tosses Hospitals' Suit Over $1.6B Cut To 340B Pay
- FDA Warning Wire: 4 Splashy New Smackdowns
- 3 Pros, 3 Cons Of Litigation Finance
- A Lawyer's Guide To Genomics In Toxic Tort Cases: Part 1
- Engineering Co. Failed To Vet Plans, Builders Say In $13M Suit
- Ex-Drug Exec Gets 15 Years For $50M Pill Distribution Plot
- Allergan Awarded $27K In Sanctions In Compounding Suit
- RICO Indictment Against Ex-Insys Execs Perplexes Judge
- Praxair's New Twist On Subject Matter Ineligibility
- Diabetes Monitoring Co. Hits Ch. 11, Seeks Sale To Creditor
- Accountant Blames $18M Fraud On VC's Ego As Trial Wraps
- AbbVie Protests FTC Interest Hike In AndroGel Case
- Costco, Abbott Win Nutritional Drink Sales Tax Suit On Appeal
- Don't Rethink OK'ing Fanapt Patent, Vanda Tells Fed. Circ.
- Online Pharmaceuticals – But Not Much Online Liability
- OvaScience Investors Cannot Overtake Rival Class Action
- Wealth Manager Leads 4 IPO Launches Surpassing $1.1B
- Modern Communication Brings E-Discovery Challenges
- Federal Cannabis Legalization May Be Closer Than You Think
- Prepare For New Claim Construction Standard At PTAB
- Indivior Wins Bid To Block Sales Of Suboxone Generic
- Two Zeneca Defenses Nixed In $275M Chancery Drug Dispute
- EPA 'Amazingly Wrong' On Roundup Cancer Risk, Jury Hears
- Insulin Device Maker Settles Shareholder Derivative Suit
- Novartis Slams Sens.' Report About Michael Cohen Contract
- Fed. Circ. Upholds PTAB Ax Of 7 Xyrem Patents
- Bard Prevails In 3rd Bellwether Case Over Late Filing
- Spine Surgery Co. Says Competitor Claims Belong In Calif.
- 14 Firms To Guide IPOs Exceeding $1.1B As Deals Resume
- Fed. Circ. OKs Endo Win In Testosterone Therapy Patent Case
- NY Could Raise Up To $678M From Legal Pot, Report Says
- It's Not All About The Benjamins, Baby (Lawyer)
- FTC Wants To Keep Fighting Opana Pay-For-Delay Deal
- Shearman Works On $203M Alexandria-Pfizer Sale-Leaseback
- ACON Labs Cholesterol Strip IP Row Paused For ITC Probe
- Ortho's $19.5M Deal Ending Antitrust MDL Gets Initial OK
- Firm Wants Mesh MDL Fee Committee To Explain Hour Cuts
- Merck Beats Shareholder Row Over Tax Liability Disclosure
- Tax Implications For The California Cannabis Industry
- Novartis Beats PTAB Challenge To MS Drug Patent
- Mass. Biotech Company Closes $132M Series A Fundraising
- Judging A Book: Hood Reviews 'Lawyering From The Inside Out'
- Digital Health Opportunities And Considerations For PE
- Health Hires: King & Spalding, DLA Piper, Polsinelli, Quarles
- Acetris Case Clarifies Definition Of 'US-Made End Product'
- Monsanto's Roundup Tied To Cancer, Ex-NIH Official Testifies
- 1.6 Billion Opioid Doses Flooded Mo., McCaskill Says
- Chancery Nixes Most Of Suit Over $600M DAVA-Endo Merger
- Drug Wholesaler Not Covered For DEA Action Over Opioids
- Get Ready For Digital Health Product Liability Cases
- Insurers' New York Pfizer Coverage Suit Bites The Dust
- J&J Hit With $4.69B Verdict In 22-Woman Talc Cancer Trial
- J&J Says Talc-Cancer Link 'Fiction' At 22-Woman Trial's Close
- Kavanaugh Splurged On Baseball Tix, Reports Say
- IP Pros Urge High Court To Hear Inequitable Conduct Case
- FisherBroyles Adds Litigators in Florida, Philadelphia
- Merus Awarded $10.5M In Mouse Patent Fight
- 4 Kavanaugh Arguments You Gotta Hear
- DEA Finalizes Prescription Opioid Anti-Diversion Policy
- Kennedy's Legacy Remains Alive In Kavanaugh's Nomination
- Forbion's 4th Fund Hits 1st Close After Raising €270M
- Senate Panel Gearing Up For Kavanaugh Vetting Fight
- Otsuka Pharmaceutical Buys Mass. Biotech For $430M In Cash
- What Civil Rights Rulings Could Look Like Under Kavanaugh
- Rite Aid Booted, Walgreens Stuck In Suit Over Failed Merger
- Shire Gets $1M Less In Atty Fees Than Sought In Drug Win
- 3 Top E-Discovery Case Law Lessons Of 2018 (So Far)
- 'Not A Complicated Case': Kavanaugh's Straightforward Style
- Monsanto Discussed Downplaying Roundup Risks, Jury Hears
- Cosmo Hits Actavis With New Patent Suit Over Colitis Drug
- VC-Backed Biotech Co. Leads 2 IPO Launches Totaling $139M
- 'Shaky' Evidence Of Roundup-Cancer Link Admissible At Trial
- Dems Need Unified Front To Combat Trump's High Court Pick
- 5 Tips For Kavanaugh As Confirmation Gets Underway
- Wave Of FDA Suits Awaits If Kavanaugh Helps Trim Chevron
- Biomet Says It Needs Confidential Docs in Trade Secrets Row
- Highmark Nixed Health Plan To Drop Hemophiliacs, Suit Says
- With Kavanaugh's Nomination, Chevron's Future Looking Grim
- Cancer-Focused Vaccinex Joins IPO Party With $46M Offering
- Pfizer Gets Another Chance In Rituxan Patent Challenge
- Law Schools Must Take A Stand Against Mandatory Arbitration
- Atty Conflict Sinks Class Cert. Against Supplement Maker
- Biotech Co. Slams 'Rapacious Individuals' In $28M TM Suit
- Maine Court Strikes A Blow Against Medical Marijuana Users
- Ex-Akebia, Merrimack Analysts Found Guilty Of Insider Trades
- New Bill Addresses Systemic Risk In Cannabis Banking
- US Regulators Give Takeda Clearance For £46B Shire Deal
- How Kavanaugh's Conservative Cred, DC Ties Won The Day
- Senate Battle Lines Drawn With Kavanaugh As Trump's Pick
- Colgate Settles Baby Powder Cancer Claims On Eve Of Trial
- Pfizer, Insurer Venue Bids Denied In Coverage Fight
- Monsanto Fights Cancer Claims In 1st Roundup Jury Trial
- 5 Kavanaugh Opinions You Need To Read Right Now
- Trump Picks Brett Kavanaugh For Supreme Court
- DEA Doubles Down On Protecting Drug Info In Opioid MDL
- 9 IPO Launches Exceeding $1.2B Rev Up July Pipeline
- PTAB Will Review 2 Patents For Shire's ADHD Drug Mydayis
- Biotech Co. Didn't Disclose Rejected Patent, Investors Say
- Goodwin Steers $315M Abingworth Life Sciences Fund Close
- Atty's Claims Back Up Penalties In Biotech Fraud, SEC Says
- Ex-Akebia Employee Denies Trading On Drug Trial Results
- Ocular Looks To Kick Investor Suit Over Eye Drug Approval
- What You Need To Know For The Supreme Court Nomination
- FDA Releases Draft Guidance On Drug Indication Labeling
- Nevro Patents Likely Nixed From Row With Boston Scientific
- Colgate Dodges Discovery Sanctions In Benefits Dispute
- Fed. Circ. Backs Wright Medical's Patent Win On Surgical Tool
- Ill. Pharmacy Wins Class Cert. In TCPA Suit Over Drug Faxes
- Don't Wait For High Court, Reed Smith Widow Tells 7th Circ.
- Fed. Circ. OKs $14M For Gilead After Merck's Patent Lies
- 2nd Circ. Anthem, Express Scripts Pricing Row Rages On
- CVS Sued Over 'Memory-Enhancing' Dietary Supplement
- Myths And Facts About Using TAR Across Borders
- USTR Rolls Out Waiver Process For New China Tariffs
- The Lipitor MDL Court Did Its Job Correctly
- Turing, Shkreli Assail DQ Bid Targeting Fox Rothschild
- Halt Medical Resists US Trustee's Move To Convert Case
- Prothena Hit With Stock-Drop Suit After Failed Clinical Trials
- Osco Drug Wants Sanctions In Prescription Refill TCPA Suit
- French Biotech Nabs €47M In Andera-Led Funding Round
- Vaccine Mandates And Lessons On Legal Compliance
- Drug Cos. Assail Hospital Bellwether In Opioid MDL
- Merck Patent Case Supports Use Of 'Unclean Hands' Defense
- Trump's China Tariffs Take Hold As Biz Groups Sound Alarm
- Atty Pushes To Arbitrate Legal Malpractice Suit
- J&J Expert Says Talc Plaintiffs Had Other Cancer Causes
- Baxter, Hospira Freed From Saline Price-Fixing Case For Now
- Genentech Sues Eli Lilly For Violating Just-Issued Drug Patent
- Bristol-Myers, Otsuka Beat Suit Over Abilify Side Effects
- Insider-Trading Suspect Says He Lied To Friend, Not Feds
- Pa. Justices To Mull Risperdal Breast-Growth Time Limit
- Deals Rumor Mill: Bristol-Myers Squibb, Aramco, Abraaj
- $140M Verdict Against AbbVie In Testosterone MDL Tossed
- MSN, Sandoz Settle Sunovion's IP Suit Over Latuda Generics
- Heart Meds Recalled In UK, EU, For Possible Cancer Link
- Baker Donelson Blasts DQ Bid In BCBS Antitrust Row
- The Top Patent Cases Of 2018: Midyear Report
- Law360 Reveals The Global 20 Firms Of 2018
- How Smaller Firms Can Go Global Without Going Bankrupt
- Global Law Firms Bulk Up In Europe As Brexit Approaches
- Direct Drug Purchasers Aim For Consolidation In Zetia MDL
- Some Good Prop 65 News For Businesses
- Feds Rework 'Misleading' Key Data For Insider-Trading Trial
- FDA Warning Wire: Pfizer Promo Video Eyed
- Three Firms Guide Catalent's $140M Pharma Biz Buy
- What The AbbVie Decision Says About Sham Patent Cases
- Medical Pot Smoking Ban Stays In Place As Fla. Fights On
- Chinese BioPharma Co. Lands $86.73M Private Placement
- Drug Wholesalers Ask For Cert. Over Lamictal Generic Delay
- Boston Scientific Can't Toss 800 Pelvic Mesh Suits
- From Lawmaker To Lawyer
- Lexion Gets SurgiQuest 'Tube' Patent Axed By PTAB
- The Sharpest Dissents From The Supreme Court Term
- High Court Nomination Watch: 7th Circ.'s Amy Coney Barrett
- Narrow Rulings Reveal Wide Gulfs Between Justices
- 4 High Court Lineups That Might Surprise You
- The Funniest Moments Of The Supreme Court Term
- Abbott Must Look Again For Docs Sought By Alere Investors
- Mitsui Stole Trade Secrets And Broke NDA, Florida Co. Says
- 23andMe DNA Patent Invalid Under Mayo, Ancestry.com Says
- Trump Plows Ahead With Supreme Court Selection Process
- Drug Cos. In Opioid MDL Must Divulge Vast Data Trove
- CVS Wants Antitrust Suit Over 340B Drug Program Tossed
- Fed. Circ. Upholds Rejection Of Artificial Glands Patent
- New Support For Insureds Facing Government Subpoenas
- Pa. Court Axes 2nd Challenge To Medical Marijuana Licenses
- A Trump Supreme Court Nominee Can Be Defeated
- The Firms That Won Big At The Supreme Court
- The Supreme Court Term By The Numbers
- The Most Talkative Justices Of The Term